Kathryn Romano Krystal Biotech, Inc. (KRYS) insider trading activity

Kathryn Romano is Chief Accounting Officer of Krystal Biotech, Inc.. Currently has a direct ownership of 19,318 shares of KRYS, which is worth approximately $3.71 Million. The most recent transaction as insider was on Feb 28, 2025, when has been sold 5,786 shares (Common Stock) at a price of $179.25 per share, resulting in proceeds of $1,037,140. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.3K

23.66% 3M change

23.66% 12M change

Total Value Held $3.71 Million

Kathryn Romano Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 28 2025	SELL Payment of exercise price or tax liability	$1,037,140 $179.25 p/Share	5,786 Reduced 23.05%	19,318 Common Stock
Feb 28 2025	BUY Exercise of conversion of derivative security	-	12,500 Added 35.42%	22,789 Common Stock
Feb 27 2025	SELL Open market or private sale	$131,415 $175.22 p/Share	750 Reduced 5.62%	12,604 Common Stock
Feb 26 2025	SELL Payment of exercise price or tax liability	$400,052 $176.39 p/Share	2,268 Reduced 14.52%	13,354 Common Stock
Feb 28 2024	SELL Payment of exercise price or tax liability	$377,367 $163.08 p/Share	2,314 Reduced 12.9%	15,622 Common Stock
Feb 28 2024	SELL Open market or private sale	$835,150 $167.03 p/Share	5,000 Reduced 27.88%	12,936 Common Stock
Feb 28 2024	SELL Open market or private sale	$1,252,200 $166.96 p/Share	7,500 Reduced 36.7%	12,936 Common Stock
Feb 28 2024	BUY Exercise of conversion of derivative security	$564,900 $56.49 p/Share	10,000 Added 35.8%	17,936 Common Stock
Feb 28 2024	BUY Exercise of conversion of derivative security	$476,625 $63.55 p/Share	7,500 Added 36.46%	13,070 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	$99,973 $52.26 p/Share	1,913 Added 12.88%	12,936 Common Stock
Feb 26 2024	SELL Payment of exercise price or tax liability	$240,681 $157.0 p/Share	1,533 Reduced 12.21%	11,023 Common Stock
Feb 26 2024	SELL Open market or private sale	$1,111,962 $137.5 p/Share	8,087 Reduced 39.18%	12,556 Common Stock
Feb 26 2024	BUY Exercise of conversion of derivative security	$422,626 $52.26 p/Share	8,087 Added 34.08%	15,643 Common Stock
Jan 22 2024	SELL Open market or private sale	$325,000 $130.0 p/Share	2,500 Reduced 16.6%	12,556 Common Stock
Jan 22 2024	BUY Exercise of conversion of derivative security	$130,650 $52.26 p/Share	2,500 Added 14.24%	15,056 Common Stock
May 22 2023	SELL Open market or private sale	$2,706,750 $108.27 p/Share	25,000 Reduced 66.57%	12,556 Common Stock
May 22 2023	BUY Exercise of conversion of derivative security	$1,353,500 $54.14 p/Share	25,000 Added 49.94%	25,056 Common Stock
May 19 2023	SELL Open market or private sale	$2,702,365 $95.06 p/Share	28,428 Reduced 69.36%	12,556 Common Stock
May 19 2023	BUY Exercise of conversion of derivative security	$1,306,500 $52.26 p/Share	25,000 Added 46.74%	28,484 Common Stock
Feb 26 2023	SELL Payment of exercise price or tax liability	$168,218 $78.46 p/Share	2,144 Reduced 11.83%	15,984 Common Stock
Feb 26 2022	SELL Payment of exercise price or tax liability	$92,000 $62.5 p/Share	1,472 Reduced 7.51%	18,128 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	19,600 Added 50.0%	19,600 Common Stock

Kathryn Romano

Chief Accounting Officer

Pittsburgh, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KRYS shares.

Notify only if

Value

Insider Trading

Get notified when an Krystal Biotech, Inc. insider buys or sells KRYS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Krystal Biotech, Inc.

Track Activities on KRYS

Account